These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2845776)

  • 1. Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2.
    Wang J; Walle A; Gordon B; Novogrodsky A; Suthanthiran M; Rubin AL; Morrison H; Silver RT; Stenzel KH
    Am J Med; 1987 Dec; 83(6):1016-23. PubMed ID: 2845776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2.
    Wang JC; Walle A; Novogrodsky A; Suthanthiran M; Silver RT; Bander NH; Rubin AL; Stenzel KH
    J Clin Oncol; 1989 Dec; 7(12):1885-91. PubMed ID: 2555451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
    Gambacorti-Passerini C; Hank JA; Albertini MR; Borchert AA; Moore KH; Schiller JH; Bechhofer R; Borden EC; Storer B; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):43-8. PubMed ID: 8435431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
    J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
    Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
    Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
    Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
    Law TM; Motzer RJ; Mazumdar M; Sell KW; Walther PJ; O'Connell M; Khan A; Vlamis V; Vogelzang NJ; Bajorin DF
    Cancer; 1995 Sep; 76(5):824-32. PubMed ID: 8625186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
    J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
    Belldegrun A; Muul LM; Rosenberg SA
    Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
    Nomura K; Fujioka T
    Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):831-40. PubMed ID: 8320888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy using lymphokine-activated killer cells.
    Fowler JE
    J Urol; 1988 Jan; 139(1):148-9. PubMed ID: 3257273
    [No Abstract]   [Full Text] [Related]  

  • 13. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
    Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
    J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
    Chang AE; Li Q; Jiang G; Sayre DM; Braun TM; Redman BG
    J Clin Oncol; 2003 Mar; 21(5):884-90. PubMed ID: 12610189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periodate and recombinant interleukin-2-activated autologous leukocytes can induce regression of metastases of renal cancer.
    Walle AJ; Wang J; Novogrodsky A; Suthanthiran M; Gordon B; Rubin AL; Stenzel KH
    Cancer Detect Prev; 1988; 12(1-6):395-411. PubMed ID: 2846172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of large doses of IL-2-activated human leukocyte antigen haploidentical peripheral blood stem cells on refractory metastatic renal cell carcinoma.
    Cao S; Wang YL; Ren XB; Yu JP; Ren BZ; Zhang XW; Zhang WH; Han Y
    Cancer Biother Radiopharm; 2011 Aug; 26(4):503-10. PubMed ID: 21812652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
    Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor properties of lymphocytes activated by the oxidizing mitogens.
    Wang J; Suthanthiran M; Walle A; Lagman M; Schwartz R; Murthi V; Novogrodsky A; Stenzel KH
    J Immunol; 1986 Jun; 136(12):4735-9. PubMed ID: 3011903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.